← All Ptc Therapeutics, INC filings

Ptc Therapeutics, INC 8-K filings

NASDAQ
PTCT
Ptc Therapeutics, INC
8-K: PTC Therapeutics Amends Royalty Agreement, Secures $250 Million and Reports Positive Interim Data for Huntington's Disease Drug
PTC Therapeutics has amended its royalty agreement, receiving $250 million, and announced positive interim results from its Huntington's disease drug trial, leading to the lifting of an FDA partial clinical hold.
NASDAQ
PTCT
Ptc Therapeutics, INC
8-K: European Commission Returns Translarna Decision to CHMP for Re-evaluation, PTC Therapeutics Pauses 2024 Revenue Guidance
The European Commission has decided not to adopt the negative opinion on Translarna's marketing authorization renewal and has requested a re-evaluation, leading PTC Therapeutics to pause its 2024 revenue guidance.
NASDAQ
PTCT
Ptc Therapeutics, INC
8-K: PTC Therapeutics Reports Strong Q1 2024 Revenue and Progress on Key Regulatory Milestones
PTC Therapeutics announced strong first quarter 2024 revenue of $210 million and progress on key regulatory submissions for its pipeline products.
NASDAQ
PTCT
Ptc Therapeutics, INC
8-K: PTC Therapeutics Reports Strong 2023 Revenue Growth and Outlines Key Milestones for 2024
PTC Therapeutics announced a 34% year-over-year revenue increase for 2023, driven by its DMD franchise, and provided updates on key regulatory submissions and clinical trial progress.
NASDAQ
PTCT
Ptc Therapeutics, INC
8-K: PTC Therapeutics Faces Setback as European Agency Rejects Translarna Renewal
The European Medicines Agency's CHMP has issued a negative opinion on the renewal of conditional marketing authorization for PTC Therapeutics' Translarna, a drug for Duchenne Muscular Dystrophy.